Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Inhibrx Inc

INBX
Current price
22.74 USD +0.25 USD (+1.11%)
Last closed 22.39 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 058 838 720 USD
Yield for 12 month -22.07 %
Week
Month
Year
INBX
21.11.2021 - 28.11.2021

Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California. Address: 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037

Analytics

WallStreet Target Price

44.25 USD

P/E ratio

Dividend Yield

Current Year

+2 178 000 USD

Last Year

+7 125 000 USD

Current Quarter

+119 000 USD

Last Quarter

+30 000 USD

Current Year

+2 178 000 USD

Last Year

+7 125 000 USD

Current Quarter

+119 000 USD

Last Quarter

+30 000 USD

Key Figures INBX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -165 236 992 USD
Operating Margin TTM -38510.09 %
PE Ratio
Return On Assets TTM -38.7 %
PEG Ratio
Return On Equity TTM -399.12 %
Wall Street Target Price 44.25 USD
Revenue TTM 440 000 USD
Book Value 2.74 USD
Revenue Per Share TTM 0.01 USD
Dividend Share
Quarterly Revenue Growth YOY -57.2 %
Dividend Yield
Gross Profit TTM -107 994 000 USD
Earnings Share -4.25 USD
Diluted Eps TTM -4.25 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics INBX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History INBX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation INBX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2119.956
Price Sales TTM 2406.4517
Enterprise Value EBITDA -5.8734
Price Book MRQ 8.185

Financials INBX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators INBX

For 52 weeks

14.31 USD 32.5 USD
50 Day MA 18.45 USD
Shares Short Prior Month 5 022 119
200 Day MA 21.31 USD
Short Ratio 13.18
Shares Short 5 291 137
Short Percent 16.86 %